Study on Early Detection and Biobanking for People at High Risk of Pancreatic Cancer Observational Study Collecting Blood and Medical Data to Understand Pancreatic Cancer Risk

What this Trial Is About

Researchers are studying individuals who do not have pancreatic cancer but are considered at higher-than-average lifetime risk of developing it. This observational study aims to create a group of participants with strong family histories, specific genetic mutations, or high-risk pancreatic cysts to better detect pancreatic or other cancers early when treatment may be more effective. The study is sponsored by the Mayo Clinic and focuses on collecting data and biospecimens to help identify biomarkers for pancreatic cancer risk. Participants will undergo blood sample collection, complete questionnaires, and have their medical records reviewed. Those with pancreatic cysts may also have cyst fluid collected during standard endoscopic ultrasound fine needle aspiration procedures. This process allows the study team to gather important biological samples and clinical information without additional invasive procedures beyond usual care. During the study, participants will be followed over time with repeated biospecimen collection and medical record reviews to track health outcomes. The researchers will develop a biobank of samples and data at enrollment and continue collecting information throughout the study period, which runs until November 2029. This ongoing follow-up helps monitor changes and supports research to validate early detection methods for pancreatic cancer.

Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts